FDA Approves Supplement for HETLIOZ (Tasimelteon) by Vanda Pharmaceuticals
The FDA has approved a supplemental application for HETLIOZ, a drug containing tasimelteon.
Company
Pharmaceutical intelligence for Vanda Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.